Skip to main content

Tasigna 200mg capsules (Nilotinib)| Apple Pharmaceuticals

Tasigna 200mg capsules (Nilotinib)

Apple Pharmaceuticals


description

Tasigna is cancer drugs, the main ingredient which is used as lapatinib, which prohibits growth of the tumor cells. Nilotinib Tasigna 200mg capsules is sold under the brand name Tasigna< which is a targeted cancer medication Tasigna tablet belongs to the class of kinase inhibitors. The medicine Tasigna in children younger than Tasigna 200mg  1 year has no safety and efficacy not been established The drug Tasigna is a prescription drugs, which is used under the knowledge of medical oncologist.

DOSAGE

The usual dose of Tasigna 200mg capsules Tablet should be given as twice daily at 12 hours time intervals Tasigna must be administer on an empty stomach Taking of food should not be at least 1 hour after the dose is taken or 2 hours before the dose is taken Who are unable to taken the Tasigna capsules, the patients can be dispersed the tablet in one teaspoon of applesauce. This tablet should be administer immediately within 15 minutes Tasigna should be combination with hematopoietic Tasigna 200mg  growth factors such as erythropoietin or G-CSF Also concomitant use with hydroxyurea or anagrelide

Dosage in adult patients with Philadelphia positive CML-CP:

The regular dose of the Tasigna 200mg capsules tablet in this condition given is 300mg should be given orally as twice daily.

With resistant or intolerant Philadelphia positive CML-CP and CML-AP:

The normal dose is 400mg should be administered as orally twice in a day.

In pediatrics:

The normal dose 230mg/m2 should be administer orally twice daily The maximum dose of Tablet Tasigna 200mg.

PHARMACOKINETICS

Absorption: 
The Tasigna 200mg  has bioavailability about 50% The time of peak plasma concentration is occurred within 3 hours after administration. 
Distribution: 
The Tasigna has serum protein binding is approximately 98% The Nilotinib blood to serum ratio is 0.68 
Metabolism: 
Tasigna 200mg capsules is metabolized via CYP3A4 mediated oxidation. The prime flowing component in the blood stream is Nilotinib. 
Elimination: 
The half life period of Tasigna Tablet is approximately 17 hours. The mean apparent clearance value is 29L/hr. 
Effect of food: 
The effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal when compared to fasted patient.

MECHANISM OF ACTION

CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene.Tasigna (nilotinib) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. Binding of Tasigna to the ATP-binding site Tasigna 200mg  of BCR-ABL protein. The drug Tasigna prevents the proliferation of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML

PRECAUTION

Tasigna may cause thrombocytopenia, neutropenia and anemia, so check blood counts periodically to reduce these complications

Embryo fetal damage

While using this in pregnancy then the drug Tasigna 200mg capsules causes fetal damage Examine the patients properly who are stop the Tasigna therapy, the range of Bcr-Abl transcripts level. Use the drug with caution while using Tasigna 200mg  in patient who are suffered with Hypokalemia Hypomagnesemia Hepatotoxicity Electrolyte abnormalities

Long QT syndrome

Monitor ECG frequently Avoid concomitant use of Tasigna 200mg  with anti-arrhythmia agents Provide supportive measures

Pancreatitis and elevated lipase

Patient suffering with pancreatitis may have serum lipase levels increase, this may results in abdominal symptoms and to decrease Tasigna 200mg capsules the problems, treatment should be postponed & undergone with appropriate diagnostics. Test serum lipase value periodically.

Tumor lysis syndrome

Maintain with sufficient hydration Balance the level of uric acid before starting the treatment.

DRUG INTERACTION

While interaction of strong CYP3A inhibitors with Tasigna drug interactions leads to increase nilotinib concentrations compared to while using Tasigna 200mg  alone Concomitant use with strong CYP3A inducer leads to reduce nilotinib concentration Tasigna interaction With proton pump inhibitors: decrease the Tasigna efficacy Avoid combination of Tasigna with drugs that may prolong the QT interval like anti-arrhythmic drugs.

CONTRAINDICATION

Tasigna tablet is contraindicated in the patients who are having; Hypokalemia Hypomagnesemia Long QT syndrome

MISSED DOSE

If patients missed to have the dose , then administer the dose of Tasigna 200mg capsules should be take within the time, or the missed dose should be swapped and continue the next dosing schedule. Consult with your doctor for more clarification

STORAGE

Stored at between Tasigna 200mg  68℉ to 77℉ (20℃ to 25℃) room temperature keep away from heat, moisture and light.

SIDE EFFECTS

Tasigna side effects, General: Fatigue, pyrexia, asthenia, peripheral edema, face edema
Pulmonary: Dyspnae , Cough, oropharyngeal pain, 
Skin: Rash, Pruritus, alopecia, dry skin
GIT: Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
Nerve system: Dizziness , Headache,
Vascular: Hypertension
Muscle: Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
Infections & infestations: Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
Eye: Eyelid edema, periorbital edema
Psychiatric: Insomnia, this are the tasigna side effects.

Contact Us


phone No      :9987711567

Email             :info@myapplepharma.com


website

Comments

Popular posts from this blog

Olimab 60mg injection | Denosumab 60mg |Apple pharmaceuticals

Olimab 60mg injection | Denosumab 60mg Apple pharmaceuticals Olimab 60mg | Olimab 60mg injection | Denosumab 60mg | Denosumab 60mg tablet Olimab 60mg injection ( Denosumab ) Olimab 60mg  belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the  Olimab 60mg   inhibition and treatment of bone metastases. Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids. Each heavy chain contains of 448 amino acids with  Olimab 60mg   4 intramolecular disulfides. PRESCRIBED Treatment for patients having postmenopausal women with  Olimab 60mg   osteoporosis at high risk for fracture. Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic pros

Afatinib 20mg | Afatinib 20mg tablet | Xovoltib | Apple pharmaceuticals

Afatinib 20mg | Afatinib 20mg tablet   Apple pharmaceuticals Afatinib 20mg | Afatinib 20mg tablet |  Xovoltib 20mg | Xovoltib 20mg tablet Afatinib 20mg tablet Xovoltib 20mg  belongs to quinazoline and butanamide derivative which acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER. Xovoltib 20mg  is a prescription drugs which is used under the guidance of medical practioners. INDICATION Xovoltib 20mg  is indicated for treatment a certain type of lung cancer (non-small cell lung cancer) which has spread to other parts of the body. DOSAGE Xovoltib the prescribed dose for the treatment of non-small cell lung cancer as follows : For adult : The prescribed dose is 40mg taken once per day. For child dosage : Ages of 0-17 years is not being studied in children. The drug should not be used age under 18 years of age For renal impairment: pr

Prolia 60mg | Prolia 60mg Injections | denosumab | Apple pharmaceuticals

Prolia 60mg | Prolia 60mg Injections | denosumab   Apple pharmaceuticals Prolia 60mg | Prolia 60mg Injections | denosumab  60mg |  denosumab  Injections Prolia 60mg | Prolia 60mg Injections Prolia 60mg   belongs to novel, fully human IgG2 monoclonal antibody especially to receptor activator of nuclear factor kappa-B ligand (RANKL), restrain bone resorption markers in patients with a difference of metastatic tumors and is being examined in multiple clinical trials for the inhibition and treatment of bone metastases. Chemically, it exists of 2 heavy and 2 light chains. Each light chain contains of 215 amino acids. Each heavy chain contains of 448 amino acids with 4 intramolecular disulfides. PRESCRIBED FOR Treatment for patients having postmenopausal women with osteoporosis at high risk for fracture. Treatment for patients with increase bone mass in men at more risk for fracture getting androgen deprivation therapy for non-metastatic prostate cancer. Treatment